Azad N - Search Results

1

Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.

Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC. Azad N, et al. Mol Cell Proteomics. 2013 Jun;12(6):1621-31. doi: 10.1074/mcp.M112.026427. Epub 2013 Feb 28. Mol Cell Proteomics. 2013. PMID: 23449826 Free PMC article. Clinical Trial.

2

Proteomics in clinical trials and practice: present uses and future promise.

Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC. Azad NS, et al. Mol Cell Proteomics. 2006 Oct;5(10):1819-29. doi: 10.1074/mcp.R600008-MCP200. Epub 2006 May 30. Mol Cell Proteomics. 2006. PMID: 16737951 Free article. Review.

3

The ongoing evolution of proteomics in malignancy.

Dhamoon AS, Kohn EC, Azad NS. Dhamoon AS, et al. Drug Discov Today. 2007 Sep;12(17-18):700-8. doi: 10.1016/j.drudis.2007.07.015. Epub 2007 Aug 24. Drug Discov Today. 2007. PMID: 17826682 Review.

4

Proteomics as a tool for biomarker discovery.

Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Kohn EC, et al. Among authors: azad n. Dis Markers. 2007;23(5-6):411-7. doi: 10.1155/2007/967023. Dis Markers. 2007. PMID: 18057524 Free PMC article. Review.

5

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC. Azad NS, et al. Cancer. 2008 Apr 15;112(8):1726-32. doi: 10.1002/cncr.23374. Cancer. 2008. PMID: 18300236 Free article. Clinical Trial.

6

Ovarian cancer in the proteomics era.

Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC. Annunziata CM, et al. Among authors: azad n. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:1-6. doi: 10.1111/j.1525-1438.2007.01096.x. Int J Gynecol Cancer. 2008. PMID: 18336391 Review.

7

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Azad NS, et al. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.

8

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH. Azad NS, et al. Clin Cancer Res. 2009 Feb 15;15(4):1411-6. doi: 10.1158/1078-0432.CCR-08-1141. Clin Cancer Res. 2009. PMID: 19228742 Free PMC article.

9

A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.

Azad N, Perroy A, Gardner E, Imamura CK, Graves C, Sarosy GA, Minasian L, Kotz H, Raggio M, Figg WD, Kohn EC. Azad N, et al. Cancer Biol Ther. 2009 Oct;8(19):1800-5. doi: 10.4161/cbt.8.19.9593. Cancer Biol Ther. 2009. PMID: 19738417 Free PMC article. Clinical Trial.

10

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.

Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC. Lee JM, et al. Among authors: azad n. Br J Cancer. 2010 Feb 2;102(3):495-9. doi: 10.1038/sj.bjc.6605514. Epub 2010 Jan 5. Br J Cancer. 2010. PMID: 20051952 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

337 results

Search Page